Bharat Immunologicals & Biologicals Corporation Ltd's earnings have declined by -233.1%, whereas share price has appreciated 28.4% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.
Bharat Immunologicals & Biologicals Corporation Ltd share price has appreciated 20.5% annually (CAGR) over the past ten years.
Data is not available for this company.
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.
BIBCOLâ€™s principal mission is to save the
BIBCOLâ€™s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination. Since its inception, it has contributed significantly to the eradication of Poliomyelitis in the country through the National Immunization Program. BIBCOL is the pioneer in the field of polio vaccines, capturing 60% of total market share in India. The company has achieved a turnover of Rs.30.53 crores during the fiscal year 2005-2006 and earned a net profit of Rs.88.08 Lakhs. Based on the performance of the company and its world class WHO-cGMP certified infrastructure, highly skilled manpower and constant support from DBT, Government of India, BIBCOL is one among the top 20 Biotech companies in India, as revealed by recent market surveys.
Business area of the company:
The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh.
The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1,2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary moneky kidney cell culture. Each dose contains Poliovirus type 1 = 106.0Poliovirus type 2 = 105.0Poliovirus type 3 = 105.8The vaccine contains stabilizers and traces of antibiotics.Doses: 0.1 ml (two drops)Packing Size: 3 ml vial contains 20 doses of OPVStorage: Vaccine is potent if stored at -20oC for 2 years
The trivalent OPV manufactured by BIBCOL is of excellent quality and complies with the GMP requirements of Shedule M of Drugs & Cosmetics Act of Government of India.